Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Travere Therapeutics's Enterprise Value is $6,362.2 Mil.
Travere Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $92.7 Mil. Therefore, Travere Therapeutics's EV-to-OCF for today is 68.63.
The historical rank and industry rank for Travere Therapeutics's EV-to-OCF or its related term are showing as below:
TVTX'
s EV-to-OCF Range Over the Past 10 Years
Min: -2990.86 Med: -11.71 Max: 405.53
Current: 68.63
During the past 13 years, the highest EV-to-OCF of Travere Therapeutics was 405.53. The lowest was -2990.86. And the median was -11.71.
TVTX's EV-to-OCF is ranked worse than 96.16% of 1407
companies
in the Biotechnology industry
Industry Median: -3.39
vs TVTX: 68.63
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Travere Therapeutics's PE Ratio (TTM) for today is calculated as:
Travere Therapeutics's share price for today is $66.14.
Travere Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.460.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Travere Therapeutics EV-to-OCF Related Terms
Travere Therapeutics EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Travere Therapeutics's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Travere Therapeutics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Travere Therapeutics EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Travere Therapeutics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Travere Therapeutics's EV-to-OCF falls into.
Travere Therapeutics's current Enterprise Value is $6,362.2 Mil.
Travere Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $92.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Travere Therapeutics (TVTX) has a EV-to-OCF of 68.63 as of Sep. 13, 2026. According to the industry distribution chart, Travere Therapeutics ranks #1353 out of 1407 companies in the Biotechnology industry, placing it in the top 96.2%.
Is Travere Therapeutics' EV-to-OCF too high?
Travere Therapeutics' current EV-to-OCF is 68.63. Based on the distribution chart, Travere Therapeutics ranks #1353 out of 1407 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Travere Therapeutics has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Travere Therapeutics' EV-to-OCF compare to ERAS and ORKA?
According to the Biotechnology industry distribution chart, Travere Therapeutics ranks #1353 out of 1407 companies for EV-to-OCF. This places Travere Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Travere Therapeutics's current EV-to-OCF is 68.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Travere Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Travere Therapeutics (TVTX) is currently considered Significantly Overvalued. The stock's GF Value™ is $37.89, compared to a current price of $66.14 — trading 74.6% above its estimated fair value. The current EV-to-OCF is 68.63. Travere Therapeutics' overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Travere Therapeutics (TVTX), the current EV-to-OCF is 68.63 as of Sep. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Travere Therapeutics (TVTX) Overvalued in 2026?
Based on GuruFocus' analysis, Travere Therapeutics stock appears to be overvalued.
The current stock price of $66.14 is trading 74.6% above its estimated GF Value™ of $37.89.
GuruFocus considers Travere Therapeutics to be Significantly Overvalued.
Key valuation signals for TVTX:
EV-to-OCF: 68.63
GF Value™: $37.89 vs. price of $66.14 (74.6% above fair value)
No single metric tells the full story. See the TVTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
61GF Score
Get the complete analysis for TVTX
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TVTX has been successfully added to your 
